(2S)-2-methyl-5-phenylpent-4-ynoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2S)-2-methyl-5-phenylpent-4-ynoic acid
• 化学式: C₁₂H₁₂O₂
• 分子量: 188.22
• InChiKey: HKDYMZFUGOUTRY-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS<br/>[FR] COMPOSITIONS DE DIFLUOROLACTAME DESTINÉES À DES MALADIES ET DES AFFECTIONS OSSEUSES MÉDIÉES PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014015246A1

  公开（公告）日：2014-01-23

  Disclosed herein are compositions and methods of treating osteroporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification.

  披露的是通过给予公式(I)化合物的组合物和方法来治疗骨质疏松症、骨折、骨丢失以及增加骨密度，其中组合物包含公式(I)的化合物和药用可接受的载体，其中L1、L2、L4、R1、R4、R5、R6和s按说明书定义。
• [EN] LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS<br/>[FR] COMPOSÉS LACTAMES EN TANT QU'AGONISTES SÉLECTIFS DU RÉCEPTEUR EP4 POUR L'UTILISATION DANS LE TRAITEMENT DE MALADIES ET D'ÉTATS À MÉDIATION PAR EP4
  申请人：CAYMAN CHEMICAL CO INC

  公开号：WO2014144610A1

  公开（公告）日：2014-09-18

  Disclosed herein are compounds of formula (I) wherein L1, L2, L3, R1, R4, R5, and R6 are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, osteoporosis, bone fracture, periodontal bone loss, orthopedic implant, alopecia, neuropathic pain, and related disorders. Pharmaceutical compositions and methods of treating conditions or disorders are also described.

  披露了公式(I)的化合物，其中L1、L2、L3、R1、R4、R5和R6如说明书定义。公式(I)的化合物是EP4激动剂，可用于治疗青光眼、骨质疏松症、骨折、牙周骨丢失、骨科植入物、脱发、神经性疼痛及相关疾病。还描述了药物组合物和治疗条件或疾病的方法。
• DIFLUOROLACTAM COMPOSITIONS FOR EP4-MEDIATED OSTEO RELATED DISEASES AND CONDITIONS
  申请人：Cayman Chemical Company, Inc.

  公开号：US20150174099A1

  公开（公告）日：2015-06-25

  Disclosed herein are compositions and methods of treating osteoporosis, bone fracture, bone loss, and increasing bone density by administration of compounds of formula (I) or compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier, wherein L 1 , L 2 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification.

  本文披露了使用式(I)化合物或包含式(I)化合物和药物可接受载体的组合物治疗骨质疏松症、骨折、骨质流失和增加骨密度的方法和组合物。其中，L1、L2、L4、R1、R4、R5、R6和s如规范中所定义。
• DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS
  申请人：Cayman Chemical Company, Inc.

  公开号：US20150175538A1

  公开（公告）日：2015-06-25

  Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L 1 , L 2 , L 4 , R 1 , R 4 , R 5 , R 6 , and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.

  本文公开了式(I)的化合物及使用该化合物的治疗方法，其中L1、L2、L4、R1、R4、R5、R6和s的定义如规范中所述。式(I)的化合物是EP4激动剂，可用于治疗青光眼、神经病性疼痛和相关疾病。
• METHODS OF SYNTHESIZING A DIFLUOROLACTAM ANALOG
  申请人：CAYMAN CHEMICAL COMPANY, INC.

  公开号：US20160060253A1

  公开（公告）日：2016-03-03

  The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R 1 , R 4 , R 5 , R 6 , and L 1 are as defined herein. Compounds of formula (IA) have been found useful as EP 4 receptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders.

  本发明涉及制备式（IA）化合物的过程和中间体，其中R1、R4、R5、R6和L1如本文所定义。式（IA）化合物已被发现在治疗青光眼、骨质疏松症、神经病性疼痛和相关疾病中作为EP4受体激动剂而有用。